Paper Details

  1. Home
  2. Paper Details

Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.

Author: CurtisJeffrey R, Navarro-MillánIris, SinghJasvinder A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Tocilizumab (TCZ) is a new medication for rheumatoid arthritis (RA) patients who have not responded well to other treatments, like anti-TNF therapies. It blocks a specific inflammatory protein in the body.
Paper Details　
Original Abstract of the Article :
Tocilizumab (TCZ), a humanized anti-interleukin-6 receptor monoclonal antibody, represents a new treatment strategy for patients with rheumatoid arthritis (RA) and is currently approved in the United States for RA patients who have failed to improve with at least one anti-tumor necrosis factor thera...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/22444783

データ提供：米国国立医学図書館（NLM）

Tocilizumab: A new biologic agent for rheumatoid arthritis

Rheumatoid arthritis is a chronic inflammatory disease that can cause pain, stiffness, and joint damage. This systematic review explores the efficacy of tocilizumab (TCZ), a humanized anti-interleukin-6 receptor monoclonal antibody, as a treatment for rheumatoid arthritis. It's like searching for a new path through the desert of arthritis research, seeking a more effective and targeted treatment.

TCZ: A targeted approach to treating rheumatoid arthritis

The researchers examined the available evidence on TCZ, a new biologic agent that targets the interleukin-6 receptor. It's like identifying a new oasis, a source of relief for those suffering from rheumatoid arthritis. They found that TCZ is effective in treating rheumatoid arthritis, particularly in patients who have not responded to other therapies.

Navigating the treatment options for rheumatoid arthritis

This review highlights the potential of TCZ as a new treatment option for rheumatoid arthritis. It's important to consult with a healthcare professional to determine if TCZ is the right treatment for you.

Dr. Camel's Conclusion

This review provides valuable information for patients with rheumatoid arthritis, highlighting the potential of TCZ as a new and effective treatment option. It's a reminder that even in the vast and challenging desert of arthritis research, we can find new oases of hope and healing.
Date :
  1. Date Completed 2012-08-06
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22444783

DOI: Digital Object Identifier

NIHMS481802

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.